QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Constenla, M. Search for Related Content PubMed PubMed Citation Articles by Constenla, M.

ONCOLOGY

5-HT₃ Receptor Antagonists for Prevention of Late Acute-Onset Emesis

Jefe de Servicio de Oncología, Complejo Hospitalario de Pontevedra, C/Loureiro Crespo, 2, 36001 Pontevedra, Spain, fax 34 986 80 70 80, mconstenla{at}nexo.es

Reprints: Manuel Constenla MD

OBJECTIVE: To review the currently available literature on the efficacy of the 5-HT₃ receptor antagonists in the prevention of late acute-onset chemotherapy-induced nausea and vomiting (12–24 h after cytotoxic treatment).

DATA SOURCES:Primary articles were identified by PubMed search (performed in March 2004) and through secondary sources. Search terms included granisetron, ondansetron, tropisetron, dolasetron, acute, chemotherapy, nausea, and vomiting (a further search was performed for palonosetron in March 2004).

STUDY SELECTION AND DATA EXTRACTION: All studies that performed regular assessments (every 2–6 h) of antiemetic control over the first 24 hours with 5-HT₃ receptor antagonists were evaluated.

DATA SYNTHESIS: Current guidelines recommend the use of 5-HT₃ receptor antagonists for the control of chemotherapy-induced nausea and vomiting but do not differentiate between the available agents. However, there is variability in the pharmacokinetic and pharmacodynamic profiles of these agents, and this has implications for dosing regimen, safety, efficacy, and potential drug–drug interactions. Cytotoxic agents vary in the time profile of their emetic effect; this must be considered when choosing an appropriate 5-HT₃ receptor antagonist. The optimal agent should be simple to administer and provide safe and effective antiemetic protection over the whole 24-hour period.

CONCLUSIONS: The differences between the 5-HT₃ receptor antagonists have important consequences for their dosing and efficacy in the control of late acute-onset chemotherapy-induced nausea and vomiting.

Key Words: antiemetics, chemotherapy, 5-HT₃ receptor antagonists, nausea and vomiting

Published Online, August 17, 2004. www.theannals.com, DOI 10.1345/aph.1D191

This article has been cited by other articles:

				B. C. De Jonghe and C. C. Horn Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus) Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R902 - R911. [Abstract] [Full Text] [PDF]

				D. D. Kloth New pharmacologic findings for the treatment of PONV and PDNV Am. J. Health Syst. Pharm., January 1, 2009; 66(1_Supplement_1): S11 - S18. [Abstract] [Full Text] [PDF]

				C. Rojas, M. Stathis, A. G. Thomas, E. B. Massuda, J. Alt, J. Zhang, E. Rubenstein, S. Sebastiani, S. Cantoreggi, S. H. Snyder, et al. Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor Anesth. Analg., August 1, 2008; 107(2): 469 - 478. [Abstract] [Full Text] [PDF]